Clinical trials: Persistent Cervical Carcinoma
Cervical Cancer
A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer
This is an open-label study to evaluate the safety, tolerability, and immunogenicity of INO-3112 DNA vaccines delivered by electroporation (EP) to female participants with HPV-16 and/or 18-positive cervical carcinoma.
- Trial name
- NCT02172911
- Testing
- INO-3112, CELLECTRA™-5P
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Inovio Pharmaceuticals
Cervical Cancer, Cervical Cancer Recurrent
SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer
The purpose of this study is to see if treatment with atezolizumab and stereotactic body radiation therapy (SBRT) will improve the objective response rate (ORR) compared with atezolizumab alone in patients with recurrent…
- Conditions
- Cervical Cancer, Cervical Cancer Recurrent, Cervical Cancer Metastatic
- Trial name
- NCT03614949
- Testing
- Stereotactic body radiation therapy (SBRT), Atezolizumab
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Cervical Squamous Cell Carcinoma, Persistent
Nimotuzumab in Combined With Chemotherapy for Treatment of IVB Stage,Rrecurrent or Persistent Cervical Carcinoma
This is an multicenter, randomized，double-blind, controlled clinical study. The purpose of the study is to evaluate the clinical efficacy and safety of Nimotuzumab combined with TP regimen (Paclitaxel + Cisplatin) for treatment…
- Trial name
- NCT06781073
- Testing
- Nimotuzumab, Paclitaxel, Cisplatin
- Where
- China
- Volunteers
- 118 people
- Sponsor
- Biotech Pharmaceutical Co., Ltd.
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer
This phase II clinical trial is studying the how well veliparib, topotecan hydrochloride, and filgrastim or pegfilgrastim work in treating patients with persistent or recurrent cervical cancer.
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma
- Trial name
- NCT01266447
- Testing
- Filgrastim, Laboratory Biomarker Analysis, Pegfilgrastim
- Where
- 78 sites in United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Intraepithelial Neoplasia (CIN), Cervical Cancer
Correlation Between Selenium Levels in Human Tissues and HPV-related Cervical Lesions and Outcomes
This study investigates the relationship between selenium levels in human tissues and the persistence of HPV (human papillomavirus) infection, particularly focusing on cervical-related lesions.
- Conditions
- Cervical Intraepithelial Neoplasia (CIN), Cervical Cancer, Persistent HPV Infection
- Trial name
- SeHPV (NCT06665841)
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital of Wenzhou Medical University
Cervical Cancer
A Clinical Study to Explore the Efficacy and Safety of Tislelizumab in Combination With Bevacizumab and Chemotherapy in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
Efficacy and safety of Tislelizumab combined with Bevacizumab and chemotherapy in patients with persistent, recurrent or metastatic cervical cancer.
- Trial name
- NCT05247619
- Testing
- Tislelizumab / Bevacizumab/Paclitaxel/Cisplatin/Carboplatin
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Zhejiang Cancer Hospital
Cervical Cancer
Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00101192
- Testing
- cetuximab, cisplatin
- Where
- 18 sites in United States
- Volunteers
- 76 people
- Sponsor
- Gynecologic Oncology Group
Cervical Cancer
Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical Cancer
This study is to assess safety as defined by the frequency and severity of gastrointestinal (GI) perforation/fistula, GI-vaginal fistula and genitourinary (GU) fistula in participants treated with bevacizumab 15 milligrams per…
- Trial name
- NCT02467907
- Testing
- Bevacizumab, Carboplatin, Paclitaxel
- Where
- 43 sites in Argentina, Brazil and 16 more
- Volunteers
- 152 people
- Sponsor
- Hoffmann-La Roche
Persistent, Recurrent, or Metastatic Cervical Cancer
A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
This is a randomized, double-blind, placebo-controlled phase III study to evaluate GLS-010 plus platinum-containing chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic…
- Trial name
- NCT05798819
- Testing
- GLS-010, paclitaxel, cisplatin
- Where
- China
- Volunteers
- 424 people
- Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
This randomized phase III trial studies the side effects of paclitaxel when given together with cisplatin or topotecan with or without bevacizumab and to compare how well they work in treating patients with stage IVB, cervical…
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma
- Trial name
- NCT00803062
- Testing
- Bevacizumab, Cisplatin, Laboratory Biomarker Analysis
- Where
- 549 sites in United States, Spain
- Volunteers
- 452 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Carcinoma to the Uterine Cervix, Recurrent Carcinoma Cervix
Effectiveness of Chemotherapy in Metastatic or Recurrent Carcinoma Cervix
Experience with substituting carboplatin for cisplatin is limited in advanced and recurrent cervix cancer and there has been no counterpart to GOG 158, which documented therapeutic equivalency of cisplatin/paclitaxel and…
- Conditions
- Metastatic Carcinoma to the Uterine Cervix, Recurrent Carcinoma Cervix, Cervix Carcinoma Recurrent
- Trial name
- NCT02492503
- Testing
- Paclitaxel and carboplatin
- Where
- India
- Volunteers
- 40 people
- Sponsor
- All India Institute of Medical Sciences
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Retreatment With Intratumoral Diffusing Alpha Radiation Emitters
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT04540588
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Israel
- Volunteers
- 2 people
- Sponsor
- Alpha Tau Medical LTD.
Cervical Cancer
A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer
This study was an randomized, double-Blind, placebo-controlled, multicenter Phase II/III study.
- Trial name
- NCT06755515
- Testing
- Rulonilimab, cisplatin/carboplatin + paclitaxel ± bevacizumab
- Where
- China
- Volunteers
- 510 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
METASTATIC CERVICAL CANCER
QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer
This study is a randomized, double-blind, placebo-controlled, multicenter phase III clinical study in 498 patients with persistent, recurrent or metastatic cervical cancer.Experimental: QL1706 + Chemotherapy…
- Trial name
- NCT05446883
- Testing
- QL1706, Paclitaxel injection, Cisplatin/Carboplatin
- Where
- 3 sites in China
- Volunteers
- 498 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Solid Organ Tumors
A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study
The purpose of this research study is to collect information from patient's medical records that had a test called ChemoFx® ordered and to understand how doctors may have used the results of the ChemoFx® to treat patients with…
- Trial name
- NCT01271959
- Where
- 25 sites in United States
- Volunteers
- 167 people
- Sponsor
- Precision Therapeutics
Metastatic Cervical Cancer, Persistent Cervical Cancer
PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer
This is a randomized trial evaluating the results of using of PD-1 and PD-L1 immune checkpoint inhibitors combined with chemotherapy, with or without bevacizumab, in patients with metastatic, persistent, and recurrent cervical…
- Conditions
- Metastatic Cervical Cancer, Persistent Cervical Cancer, Recurrent Cervical Cancer
- Trial name
- NCT07472153
- Testing
- PD-1 antibody, PD-L1 antibody, Chemotherapy and bevacizumab (CT-BEV)
- Where
- Belarus
- Volunteers
- 120 people
- Sponsor
- N.N. Alexandrov National Cancer Centre
Cervical Cancer
A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
This is A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate AK104 Plus Platinum-containing Chemotherapy With or Without Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical…
- Trial name
- NCT04982237
- Testing
- AK104, paclitaxel, carboplatin
- Where
- 5 sites in China
- Volunteers
- 445 people
- Sponsor
- Akeso
Cervical Cancer, Cervical Cancer Metastatic
Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA)
This is a multicenter, open-label, single-arm study of efficacy, safety and pharmacokinetics of BCD-100 (JSC BIOCAD, Russia) in combination with platinum-based chemotherapy and bevacizumab as first-line treatment in patients with…
- Conditions
- Cervical Cancer, Cervical Cancer Metastatic, Cervical Cancer Recurrent
- Trial name
- NCT03912402
- Testing
- BCD-100, Bevacizumab, Paclitaxel
- Where
- 24 sites in Russia
- Volunteers
- 49 people
- Sponsor
- Biocad
Cervical Cancer
Niraparib Combined With Brivanib or Toripalimab in Patients With Cervical Cancer
A Clinical Proof-of-concept Study Evaluating Efficacy and Safety of ZL-2306 (Niraparib) Combined With Brivanib or Toripalimab in Patients With Metastatic, Recurrent, and Persistent Cervical Cancer
- Trial name
- CQGOG0101 (NCT04395612)
- Testing
- niraparib combined with brivanib, niraparib combined with toripalimab
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Chongqing University Cancer Hospital
Human Papilloma Virus Infection, Human Papilloma Virus Integration
Diagnostic Cervical Conization for Persistent Infection or Integration of HPV
For the patients with cervical persistent infection or integration of HPV, we has designed a program to perform cervical conization for certain patients to earlier and better diagnose and cure the diseases of HPV infection and…
- Conditions
- Human Papilloma Virus Infection, Human Papilloma Virus Integration, Cervical Intraepithelial Neoplasia, Cervical Cancer
- Trial name
- NCT05510830
- Testing
- diagnostic cervical conization
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Tongji Hospital